Saturday 17 October 2026
Export TNON’s income statement to Excel — free account
Tenon Medical, Inc.
TNON Healthcare Medical Devices
Tenon Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.9 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue grew 126.8%, EPS grew 1.88% and free cash flow fell 21.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
2.70
0.21
−7.22%
Follow TNON
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.13 |
+8 more quarters Free account |
P/S ratio |
0.70 | 1.78 | 1.78 | 3.01 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.36) | (2.77) | (3.16) | (2.55) | |
P/B ratio |
0.00 | 0.00 | 3.58 | 5.65 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.45 | 0.85 | 0.92 | 2.05 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.20) | (0.35) | (0.34) | (0.59) | |
EV/FCF |
(0.19) | (0.32) | (0.31) | (0.54) | |
Quick Ratio |
0.44 | 0.89 | 1.70 | 1.56 | |
Current Ratio |
0.58 | 1.03 | 2.11 | 2.15 | |
Net Debt/EBITDA |
0.71 | 1.56 | 1.39 | 1.06 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.51 | 0.35 | 0.38 | 0.28 | |
Operating CF/Net income |
0.68 | 0.85 | 0.79 | 1.15 | |
Capex/Depreciation |
(0.18) | (0.17) | (1.17) | (4.41) | |
Interest Coverage |
(3.94) | (18.64) | — | — | |
Research and Development Expense of Revenue |
60.05% | 48.01% | 35.58% | 36.49% | |
Selling, General and Administrative Expense of Revenue |
265.83% | 258.38% | 226.60% | 318.58% | |
Intangible Assets out of Total Assets |
0.29 | 0.22 | 0.27 | 0.28 | |
Share Based Compensation of Revenue |
32.21% | 24.00% | 23.23% | 4.94% | |
Graham Net Nets |
(1.83) | (0.41) | 0.15 | 0.10 | |
Graham Number |
121.76 | 60.93 | 0.00 | 224.53 | |
Earnings Yield |
(393.23%) | (177.51%) | (208.82%) | 742.68% | |
Free Cash Flow Yield |
(342.69%) | (150.20%) | (166.70%) | (125.13%) | |
Revenue per Share |
3.90 | 4.28 | 7.01 | 4.97 | |
Operating CF per Share |
(8.41) | (9.18) | (10.53) | (16.20) | |
Capex per Share |
(0.52) | (0.17) | (0.91) | (2.71) | |
Free Cash Flow per Share |
(8.93) | (9.36) | (11.44) | (18.91) | |
Cash per Share |
5.11 | 14.29 | 17.78 | 14.58 | |
Shareholders Equity per Share |
(5.31) | 5.88 | 23.86 | 20.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(5.31) | 5.88 | 23.86 | 20.33 | |
Free Cash Flow |
(2.93) | (3.02) | (2.42) | (4.46) | |
Working Capital |
(3.50) | 0.22 | 3.56 | 3.50 | |
Capital Expenditures |
(0.17) | (0.06) | (0.19) | (0.64) | |
Net Current Asset Value |
(6.86) | (3.32) | 1.05 | 0.98 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.13 | 0.04 | 0.13 | 0.54 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.36 | 1.43 | 1.28 | 1.09 | |
Average Payables |
0.76 | 0.57 | 0.61 | 0.86 | |
Average Inventory |
0.74 | 0.71 | 0.83 | 0.99 | |
Average Assets |
10.52 | 13.12 | 10.30 | 11.70 | |
Average Common Equity |
(0.93) | 2.22 | 2.09 | 3.08 |
Columns are period end dates